Direct-to-consumer advertising of prescription medicines : a counter argument
Direct-to-consumer advertising of prescription-only medicines is currently only permitted in the USA and New Zealand. Barbara Mintzes and Dee Mangin provide their case against direct-to-consumer advertising of prescription medicines, arguing that its wider introduction would lead to a 'Pharma-knows-best' culture.
| Errataetall: |
CommentOn: Future Med Chem. 2009 Jul;1(4):587-92. - PMID 21426028 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2009 |
|---|---|
| Erschienen: |
2009 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:1 |
|---|---|
| Enthalten in: |
Future medicinal chemistry - 1(2009), 9 vom: 01. Dez., Seite 1555-60 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mintzes, Barbara [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 11.07.2011 Date Revised 10.12.2019 published: Print CommentOn: Future Med Chem. 2009 Jul;1(4):587-92. - PMID 21426028 Citation Status MEDLINE |
|---|
| doi: |
10.4155/fmc.09.136 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM206842252 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM206842252 | ||
| 003 | DE-627 | ||
| 005 | 20231224000812.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2009 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4155/fmc.09.136 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0689.xml |
| 035 | |a (DE-627)NLM206842252 | ||
| 035 | |a (NLM)21425978 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mintzes, Barbara |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Direct-to-consumer advertising of prescription medicines |b a counter argument |
| 264 | 1 | |c 2009 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 11.07.2011 | ||
| 500 | |a Date Revised 10.12.2019 | ||
| 500 | |a published: Print | ||
| 500 | |a CommentOn: Future Med Chem. 2009 Jul;1(4):587-92. - PMID 21426028 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Direct-to-consumer advertising of prescription-only medicines is currently only permitted in the USA and New Zealand. Barbara Mintzes and Dee Mangin provide their case against direct-to-consumer advertising of prescription medicines, arguing that its wider introduction would lead to a 'Pharma-knows-best' culture | ||
| 650 | 4 | |a News | |
| 650 | 4 | |a Comment | |
| 650 | 7 | |a Lactones |2 NLM | |
| 650 | 7 | |a Sulfones |2 NLM | |
| 650 | 7 | |a rofecoxib |2 NLM | |
| 650 | 7 | |a 0QTW8Z7MCR |2 NLM | |
| 700 | 1 | |a Mangin, Dee |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Future medicinal chemistry |d 2009 |g 1(2009), 9 vom: 01. Dez., Seite 1555-60 |w (DE-627)NLM194822109 |x 1756-8927 |7 nnns |
| 773 | 1 | 8 | |g volume:1 |g year:2009 |g number:9 |g day:01 |g month:12 |g pages:1555-60 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.4155/fmc.09.136 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 1 |j 2009 |e 9 |b 01 |c 12 |h 1555-60 | ||